No abstract

The effect of CDB-2914 on BS% was initially beneficial but then by third treatment was disadvantageous. Nevertheless, only 3% (4/136) of all women discontinued LNG-IUS. These findings give insight into possible mechanisms and suggest future research directions. ISRCTN Trial no. ISRCTN58283041; EudraCT no. 2006-006511-72.

No abstract

Drug review considers the risks and benefits of the current treatment options, followed by sources of further information, an analysis of prescription data and the Datafile.M uch confusion currently exists surrounding menopause management and the role of hormone replacement therapy (HRT), fuelled by publication of the much-debated Women's Health Initiative (WHI) trial 1 and the Million Women Study. 2 This review describes the treatment options currently used to treat menopausal symptoms, highlighting their risks, benefits and side-effects, in addition to suggesting a management protocol. Menopausal symptomsMenopausal symptoms are estimated to affect twothirds of women and are described as distressing in 10-20 per cent. The classic menopausal symptoms include hot flushes and night sweats, but many other symptoms -such as sleep disturbance, joint aches, irritability, mood changes, lack of confidence and genitourinary problems -have also been associated with the hormonal changes of the menopause. For many women leading extremely busy lives, balancing